Lucid Diagnostics to Present at Canaccord Genuity MedTech Forum
Lucid Diagnostics Inc. (Nasdaq: LUCD) has announced its participation in the upcoming Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York City on November 11, 2026. The company's Chairman and CEO, Lishan Aklog, M.D., is scheduled to join a panel discussion focused on oncology diagnostics and reimbursement strategies. In addition to the panel, CEO Dr. Aklog and CFO Dennis McGrath will engage in one-on-one meetings with investors. Lucid Diagnostics, a subsidiary of PAVmed Inc. (Nasdaq: PAVM), specializes in cancer prevention through its EsoGuard® DNA test and EsoCheck® collection device, targeting early detection of esophageal precancer.
Tickers: $PAVM
Topics: conference participation investor relations medical diagnostics